Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic MCC progressed on chemotherapy;Paul Nghiem et al.

At the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr Suzanne Topalian (John Hopkins Bloomberg~Kimmel Institute for Cancer Immunotherapy), presented data from CheckMate 358, a study on nivolumab as neoadjuvant therapy in patients with resectable MCC. The study showed that nivolumab administered for 4 weeks before surgery in MCC was safe and induced substantial radiologic and pathologic tumour regressions in 45% and 65% of patients, respectively. In some patients, this obviated the need for more extensive surgery. To view the presentation, please click here (Attachment no. 3)